Cargando…

A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01)

PURPOSE: Multi-tyrosine kinase inhibitors (TKI) have shown clinical activity in patients with metastatic colorectal cancer. Cabozantinib, a multi-TKI, exhibited potent antitumor activity superior to regorafenib in preclinical colorectal cancer patient-derived tumor xenograft models. This phase II st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scott, Aaron J., Basu Mallick, Atrayee, Dotan, Efrat, Cohen, Steven J., Gold, Philip J., Hochster, Howard S., Subramaniam, Somasundaram, Barzi, Afsaneh, Watts, George S., Blatchford, Patrick J., Messersmith, Wells A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035393/ https://www.ncbi.nlm.nih.gov/pubmed/36969746 http://dx.doi.org/10.1158/2767-9764.CRC-22-0169

Ejemplares similares

Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models
por: Lang, Julie, et al.
Publicado: (2022)

Impact of Immunoscore on the Management of Stage II Colon Cancer Patients: A Physician Survey
por: Kasi, Anup, et al.
Publicado: (2021)

Fever of Undetermined Origin During Neoadjuvant Chemoradiotherapy of Gastroesophageal Junction Adenocarcinoma Due to Radiation-induced Liver Disease
por: Bashir, Babar, et al.
Publicado: (2019)

Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01)
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma
por: Storandt, Michael H., et al.
Publicado: (2022)

Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
por: Vecchio, Sharon J. Del, et al.
Publicado: (2018)

Development of cabozantinib for the treatment of prostate cancer
por: Vaishampayan, Ulka N
Publicado: (2014)

Cabozantinib‐induced renal thrombotic microangiopathy
por: La Manna, Gaetano, et al.
Publicado: (2017)

Cabozantinib and apixaban: an hitherto unreported interaction
por: Santini, Daniele, et al.
Publicado: (2019)

Phase II Study of Cabozantinib in Patients With Bone Metastasis
por: Choy, Edwin, et al.
Publicado: (2022)

A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer
por: Davis, S. Lindsey, et al.
Publicado: (2019)

CRC handbook of laser science and technology
por: Weber, Marvin J
Publicado: (1982)

CRC handbook of laser science and technology
por: Weber, Marvin J
Publicado: (1982)

CRC handbook of laser science and technology
por: Weber, Marvin J
Publicado: (1986)

CRC handbook of laser science and technology
por: Weber, Marvin J
Publicado: (1986)

CRC handbook of laser science and technology
por: Weber, Marvin J
Publicado: (1987)

Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
por: Shi, Bo, et al.
Publicado: (2022)

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
por: Yoshino, Takayuki, et al.
Publicado: (2023)

Development of cabozantinib for the treatment of prostate cancer [Corrigendum]
Publicado: (2014)

Cabozantinib for the Treatment of Metastatic Medullary Thyroid Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014)

Modulation of cabozantinib efficacy by the prostate tumor microenvironment
por: Tripathi, Manisha, et al.
Publicado: (2017)

Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib
por: Scirocchi, Fabio, et al.
Publicado: (2021)

Regression of Intracranial Meningiomas Following Treatment with Cabozantinib
por: Kotecha, Rupesh, et al.
Publicado: (2021)

CRC materials science and engineering handbook
por: Alexander, William, et al.
Publicado: (1994)

Metabolic Pathways and Targets in Chondrosarcoma
por: Micaily, Ida, et al.
Publicado: (2021)

The requirement for freshly isolated human colorectal cancer (CRC) cells in isolating CRC stem cells
por: Fan, F, et al.
Publicado: (2015)

CRC handbook of basic tables for chemical analysis
por: Bruno, Thomas J.
Publicado: (1989)

Immune cell mediated cabozantinib resistance for patients with renal cell carcinoma
por: Park, Keon Young, et al.
Publicado: (2021)

Dramatic Response to Cabozantinib in a Patient with Refractory Hepatocellular Carcinoma with c-MET Amplification
por: Sang, Yun Beom, et al.
Publicado: (2023)

CRC handbook of microbiology
Publicado: (1988)

Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo
por: Haider, Marie-Therese, et al.
Publicado: (2015)

The treatment landscape in thyroid cancer: a focus on cabozantinib
por: Weitzman, Steven P, et al.
Publicado: (2015)

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
por: Kelley, Robin K., et al.
Publicado: (2020)

Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma
por: Shang, Runze, et al.
Publicado: (2021)

EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma
por: Ma, Xuhui, et al.
Publicado: (2022)

Cabozantinib for the treatment of solid tumors: a systematic review
por: Maroto, Pablo, et al.
Publicado: (2022)

SAT479 A Case of Thyroiditis Cause by Cabozantinib
por: Bulchandani, Sheetal, et al.
Publicado: (2023)

Effectiveness of Colorectal Cancer (CRC) Screening on All-Cause and CRC-Specific Mortality Reduction: A Systematic Review and Meta-Analysis
por: Zheng, Senshuang, et al.
Publicado: (2023)

CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure
por: Coquan, Elodie, et al.
Publicado: (2021)

Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy
por: Lin, Ruihe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_evnq1u3uckqvd0c4hn26s4vc0l